« Return to News | Miscellaneous

Bert Spilker's Pharma Principles of The Week

Friday, February 16, 2007 05:07 PM

Posted by: Bert Spilker

  • Ask yourself whose responsibility it is to create a strategy that will recruit patients. If you said “the investigator” you are wrong. It is the sponsor’s responsibility to create a strategy that will be successful, and if it is not, to readjust it and to apply necessary resources to insure it succeeds.
  • Open-label clinical trials often mislead a company as the data obtained have a much greater likelihood of being positive than if the same trial was done in a double blind manner.  This may lead to a company wasting years of effort and millions of dollars until hey recognize that the drug really did not demonstrate efficacy in a true double blind study.
  • Insure that any compassionate plea protocols are in your company’s interests. This requires a balance of ethical responsibilities with practical issues. The practical issues include resources required, value of the data obtained and whether your program is being slowed and allowing competitors to catch up or move ahead of you.

Bert Spilker, PhD, MD is an independent consultant who was most recently the Senior Vice President of Scientific and Regulatory Affairs for PhRMA. He is the founder of Bert Spilker & Associates (BS&A).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.